Marriott International exceeded analyst expectations with strong Q4 results, showcasing resilience in a challenging industry. EPS of $3.57 surpassed estimates ...
KalVista Pharmaceuticals achieves key goals in late-stage study for hereditary angioedema therapy, demonstrating significant efficacy of sebetralstat. FDA approval filing ...